A key molecular feature of melanoma is the frequent occurrence of activating mutations in the MAPK pathway, particularly in BRAF (most commonly the oncogenic BRAFV600E mutation), which has been successfully targeted with inhibitors such as vemurafenib (Kim and Cohen, 2016; Wellbrock and Hurlstone, 2010). This evidence concerns the gene BRAF and melanoma.